Back

Circulating Exosomal PCNA: A Biomarker for Early and Pan-Cancer Detection

Shi, W.; Sun, X.; Zhou, H.; Da, H.; Li, H.; Cai, C.

2025-02-08 cancer biology
10.1101/2025.02.06.636863 bioRxiv
Show abstract

Detecting multiple cancers with a single, non-invasive liquid biopsy test remains a challenge, as no universally shared cancer biomarker with clinical significance has been identified in bodily fluids. In this study, we identified proliferating cell nuclear antigen (PCNA), a well-established pathological cancer biomarker in tissue biopsies, as being secreted into peripheral bodily fluids within exosomes. Our research demonstrated that cultured cancer cells continuously release large quantities of exosomal PCNA into their surrounding media. Furthermore, we confirmed its presence in human serum. Most importantly, cancer patients exhibited significantly higher levels of exosomal PCNA in their sera compared to healthy individuals. To assess its diagnostic potential, we evaluated the sensitivity and specificity of exosomal PCNA in a cohort of cancer patients and healthy controls. Receiver operating characteristic (ROC) analysis revealed a sensitivity of 77.2% and a specificity of 94.4%. These findings establish exosomal PCNA in peripheral bodily fluids as a promising universal biomarker for the early detection, diagnosis, and monitoring of multiple cancers through liquid biopsy.

Matching journals

The top 12 journals account for 50% of the predicted probability mass.

50% of probability mass above

"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.